Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation

Hongqing Zhuang; Xiangkun Yuan; Joe Y. Chang; Yongchun Song; Junjie Wang; Zhiyong Yuan; Xiaoguang Wang; Ping Wang

doi:10.18632/oncotarget.7768

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation

Hongqing Zhuang _, Xiangkun Yuan, Joe Y. Chang, Yongchun Song, Junjie Wang, Zhiyong Yuan, Xiaoguang Wang and Ping Wang

PDF | HTML | How to cite

Oncotarget. 2016; 7:48842-48849. https://doi.org/10.18632/oncotarget.7768

Metrics: PDF 2124 views | HTML 2221 views | ?

Abstract

Hongqing Zhuang1, Xiangkun Yuan2, Joe Y. Chang3, Yongchun Song1, Junjie Wang4, Zhiyong Yuan1, Xiaoguang Wang1 and Ping Wang1

1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

2 Department of Radiotherapy, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine (Cangzhou No. 2 Hospital), Hebei, China

3 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

4 Department of Radiotherapy, Peking University 3rd Hospital, Beijing, China

Correspondence to:

Hongqing Zhuang, email:

Keywords: bevacizumab, brain necrosis, recurrence

Received: November 27, 2015 Accepted: February 08, 2016 Published: February 26, 2016

Abstract

Objective: The aim of the paper was to investigate the recurrence and its causes of radiation brain necrosis following bevacizumab discontinuation. Methods: This study included 14 patients with radiation brain necrosis (confirmed through imaging) after stereotactic radiotherapy for a primary or metastatic brain tumor and who received bevacizumab treatment from June 2011 through December 2014. The patients received bevacizumab at 5 mg/kg, q3-4w, for at least 3 cycles. The T1 signal intensity from enhanced MRI images was used as the evaluation criteria for the brain necrosis treatment efficacy. Results: brain necrosis improved in 13 of the 14 cases (92.9%). However, during follow-up, 10 of the 13 responsive patients (76.9%) exhibited a recurrence in brain necrosis, and a multiple linear regression analysis shows that brain necrosis recurrence was related to the follow-up time after the initial bevacizumab treatment discontinuation. Conclusion: bevacizumab produced good short-term effects for radiation brain necrosis; however, most of the patients would recurrence after bevacizumab is discontinued. Thus, brain necrosis was irreversible.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7768

Publication Alerts

Case Reports:

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation

Abstract